JPRN-UMIN000030599已完成未知
Prospective study of anti-HCV therapy with pan-genotype direct acting anti-viral agents for patients with chronic liver diseases - Study of pan-genotype anti-HCV therapy
Department of Hepatology, Osaka City University Graduate School of Medicine0 个研究点目标入组 423 人开始时间: 2018年1月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 423
研究概览
简要总结
Glecaprevir + pibrentasvir had a remarkable anti-HCV effect in GT-1 and GT-2 patients, but not in GT-3b patients. Although this therapy was reasonably safe, it is necessary to carefully consider elderly and dropout patients.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active malignant tumor including liver cancer 2)Decompensated hepatic cirrhosis 3)Prohibition of per oral drugs 4)Medication contraindication drugs to pan-genotype DAAs 5)Allergy to pan-genotype DAA 6)Unsuitable condition to the present study
研究者
相似试验
已完成
3 期
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected PatientsChronic HCV HepatitisNCT03496233Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo75
已完成
不适用
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6Hepatitis CNCT03303599AbbVie2,118
已完成
2 期
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis CHepatitis C, ChronicNCT00148863French National Agency for Research on AIDS and Viral Hepatitis65
已完成
不适用
Efficacy and safety of glecaprevir/pibrentasvir combination tablets for patients infected with pan-genotypic hepatitis C virusChronic Hepatitis CJPRN-UMIN000029652Saitama Medical University200
已完成
不适用
Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hepatitis C infected patients with chronic hepatitis or liver cirrhosisJPRN-UMIN000031090Hokkaido University Hospital300